We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Why Teladoc (TDOC) Outpaced the Stock Market Today
Read MoreHide Full Article
Teladoc (TDOC - Free Report) ended the recent trading session at $6.16, demonstrating a +1.15% change from the preceding day's closing price. The stock's performance was ahead of the S&P 500's daily gain of 0.86%. Meanwhile, the Dow gained 0.98%, and the Nasdaq, a tech-heavy index, added 0.96%.
Prior to today's trading, shares of the telehealth services provider had lost 12.5% lagged the Medical sector's loss of 2.34% and the S&P 500's loss of 1.96%.
The investment community will be paying close attention to the earnings performance of Teladoc in its upcoming release. The company's upcoming EPS is projected at -$0.22, signifying a 4.76% drop compared to the same quarter of the previous year. Meanwhile, our latest consensus estimate is calling for revenue of $585.55 million, down 6.53% from the prior-year quarter.
TDOC's full-year Zacks Consensus Estimates are calling for earnings of -$0.9 per share and revenue of $2.4 billion. These results would represent year-over-year changes of +21.05% and -5.03%, respectively.
It is also important to note the recent changes to analyst estimates for Teladoc. These latest adjustments often mirror the shifting dynamics of short-term business patterns. As a result, we can interpret positive estimate revisions as a good sign for the business outlook.
Our research suggests that these changes in estimates have a direct relationship with upcoming stock price performance. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system, ranging from #1 (Strong Buy) to #5 (Strong Sell), possesses a remarkable history of outdoing, externally audited, with #1 stocks returning an average annual gain of +25% since 1988. Over the past month, there's been a 0.83% fall in the Zacks Consensus EPS estimate. Teladoc is currently sporting a Zacks Rank of #3 (Hold).
The Medical Services industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 88, positioning it in the top 36% of all 250+ industries.
The Zacks Industry Rank assesses the strength of our separate industry groups by calculating the average Zacks Rank of the individual stocks contained within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.
View the Zacks #1 Rank List
Image: Bigstock
Why Teladoc (TDOC) Outpaced the Stock Market Today
Teladoc (TDOC - Free Report) ended the recent trading session at $6.16, demonstrating a +1.15% change from the preceding day's closing price. The stock's performance was ahead of the S&P 500's daily gain of 0.86%. Meanwhile, the Dow gained 0.98%, and the Nasdaq, a tech-heavy index, added 0.96%.
Prior to today's trading, shares of the telehealth services provider had lost 12.5% lagged the Medical sector's loss of 2.34% and the S&P 500's loss of 1.96%.
The investment community will be paying close attention to the earnings performance of Teladoc in its upcoming release. The company's upcoming EPS is projected at -$0.22, signifying a 4.76% drop compared to the same quarter of the previous year. Meanwhile, our latest consensus estimate is calling for revenue of $585.55 million, down 6.53% from the prior-year quarter.
TDOC's full-year Zacks Consensus Estimates are calling for earnings of -$0.9 per share and revenue of $2.4 billion. These results would represent year-over-year changes of +21.05% and -5.03%, respectively.
It is also important to note the recent changes to analyst estimates for Teladoc. These latest adjustments often mirror the shifting dynamics of short-term business patterns. As a result, we can interpret positive estimate revisions as a good sign for the business outlook.
Our research suggests that these changes in estimates have a direct relationship with upcoming stock price performance. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system, ranging from #1 (Strong Buy) to #5 (Strong Sell), possesses a remarkable history of outdoing, externally audited, with #1 stocks returning an average annual gain of +25% since 1988. Over the past month, there's been a 0.83% fall in the Zacks Consensus EPS estimate. Teladoc is currently sporting a Zacks Rank of #3 (Hold).
The Medical Services industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 88, positioning it in the top 36% of all 250+ industries.
The Zacks Industry Rank assesses the strength of our separate industry groups by calculating the average Zacks Rank of the individual stocks contained within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.